drugset / Trial / NCT04391101
Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)
Phase 3
Unknown
231 enrolled
Hospital San Vicente Fundación
Clínica Cardiovid · collabClínica Las Américas · collabClínica León XIII · collabClínica Rosario El Tesoro · collabClínica Universitaria Bolivariana · collabGrupo de Inmunodeficiencias primarias Universidad de Antioquia · collabHospital Pablo Tobón Uribe · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Convalescent plasma has been used for over 100 years in the treatment of severe acute respiratory infections of viral origin. There are not pharmacological treatments for the actual outbreak for SARS-Cov-2 and it is necessary to evaluate the efficacy of treatment options, including convalescent plasma transfusion. The hypothesis is that convalescent plasma is efficacious and safe for reducing mortality in patients with COVID-19 treated in ICU
Timeline
- Start
- 2020-06
- Primary completion
- 2021-06
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Convalescent Plasma | Protein / enzyme biologic | 400 ml | Other |
| Subject | Convalescent Plasma | Protein / enzyme biologic | 500 ml | Other |